典型文献
Post COVID-19 burden: focus on the short-term condition
文献摘要：
The catastrophic pandemic of the coronavirus disease 2019 (COVID-19) has caused serious harm to human life and global social economy. As of June 13, 2022, there were more than 530 million confirmed cases of COVID-19 and over 6.3 million deaths[1]. During the past 2 years, global studies on prevention and therapies for COVID-19 have achieved a series of promising findings, including antiviral drugs (Remdesivir, Molnupiravir, Paxlovid) and monoclonal antibodies (Bamlanivimab and Etesevimab, Sotrovimab, Casirivimab and Imdevimab)[2]. World Health Organization (WHO) has validated 11 vaccines for the emergency use listing (EUL)[3]. As of June 13, 2022, more than 11.9 billion vaccine doses have been administered worldwide[1]. In China, integrated using of traditional Chinese medicine (TCM) and Western medicine is one of the highlights in fighting COVID-19. "Three formulations and three drugs" (Jinhua Qinggan granules, Lianhua Qingwen capsule, Xuebijing injec-tion, and Qingfei Paidu decoction, Huashi Baidu decoc-tion, Xuanfei Baidu decoction) have been approved by National Medical Products Administration (NMPA) as new drugs or adding indications for COVID-19[4]. The new drugs and vaccines had become effective weapons in the fight against the pandemic.
文献关键词：
中图分类号：
作者姓名：
Fengwen Yang;Bo Pang;Xinyao Jin;Zhe Chen;Wentai Pang;Qingquan Liu;Junhua Zhang;Boli Zhang
作者机构：
State Key Laboratory of Component-Based Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin,China;Haihe Laboratory of Modern Chinese Medicine,Tianjin,China;Beijing Hospital of Traditional Chinese Medicine,Beijing,China
文献出处：
引用格式：
[1]Fengwen Yang;Bo Pang;Xinyao Jin;Zhe Chen;Wentai Pang;Qingquan Liu;Junhua Zhang;Boli Zhang-.Post COVID-19 burden: focus on the short-term condition)[J].针灸和草药（英文）,2022(03):139-142
A类：
Bamlanivimab,Etesevimab,Casirivimab,Imdevimab,EUL,Qingfei,Paidu,Huashi,decoc,Xuanfei
B类：
Post,burden,focus,short,term,condition,catastrophic,pandemic,coronavirus,disease,has,caused,serious,harm,human,life,global,social,economy,June,there,were,more,than,million,confirmed,cases,over,deaths,During,past,years,studies,prevention,therapies,have,achieved,series,promising,findings,including,antiviral,drugs,Remdesivir,Molnupiravir,Paxlovid,monoclonal,antibodies,Sotrovimab,World,Health,Organization,WHO,validated,vaccines,emergency,listing,billion,doses,been,administered,worldwide,In,China,integrated,using,traditional,Chinese,medicine,TCM,one,highlights,fighting,Three,formulations,three,Jinhua,Qinggan,granules,Lianhua,Qingwen,capsule,Xuebijing,injec,decoction,Baidu,approved,by,National,Medical,Products,Administration,NMPA,new,adding,indications,had,become,effective,weapons,against
AB值：
0.625698
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
